ALBO News and Press, Albireo Pharma Inc. From 06/30/20

There's a number of upcoming catalysts in the liver disease treatment space, prompting Needham to update its takes on drugmakers targeting the diseases. More news on: Intercept Pharmaceuticals, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Notable Calls ...

A look into pediatric liver diseases has Baird launching coverage on two names it sees with heavy upside, with key data and catalysts ahead. More news on: Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Notable Calls, Healthcare stocks news Read more ...

BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinical outcome assessments (COAs) on Tues...

Albireo Pharma ( ALBO -0.3% ) agrees to terms with Hercules Capital on a debt facility to provide up to $80M of new capital, and will receive $15M under a restructured royalty monetization agreement with HealthCare Royalty Partners for elobixibat for chronic constipation in Japan, w...

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital —   — Initial draw down of $10M on debt facility of up to $80M with Hercules Capital — BOSTON , June 09, 2020 (GLOBE NEW...

BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jeff...

Albireo Pharma, Inc. (ALBO) Q1 2020 Results Earnings Conference Call May 7, 2020, 10:00 AM ET Company Participants Paul Arndt - LifeSci Advisors, IR Ron Cooper - President and CEO Dr. Pat Horn - Chief Medical Officer Pamela Stephenson - Chief Commercial Officer Simon Harford ...

The following companies have recently filed for mixed shelf offerings: More news on: Albireo Pharma, Inc., ARCA biopharma, Inc., Owens & Minor, Inc., Healthcare stocks news, , Read more ...

Image source: The Motley Fool. Albireo Pharma, Inc.   (NASDAQ: ALBO) Q1 2020 Earnings Call May 7, 2020 , 10:00 a.m. ET Operator Continue reading

Albireo Pharma (NASDAQ: ALBO ): Q1 GAAP EPS of -$2.23 misses by $0.87 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...